本文關(guān)鍵詞： 纈沙坦 氨氯地平 纈沙坦聯(lián)合氨氯地平 冠心病 高血壓　出處：《吉林大學(xué)》2015年碩士論文　論文類型：學(xué)位論文

【摘要】：研究目的： 通過評估臨床對冠心病合并高血壓患者應(yīng)用纈沙坦聯(lián)合氨氯地平治療的臨床療效及可行性。 研究方法： 將2013年5月-2014年5月來我院就診治療的診斷明確的冠心病合并高血壓患者納入研究，隨機(jī)平行將患者等分成2組（每組34人），對照組給予硝苯地平緩釋片用藥，觀察組實(shí)施纈沙坦配合氨氯地平治療，研究2組的治療結(jié)局。 確診后，對本實(shí)驗(yàn)患者提供測量血壓、補(bǔ)液及對癥處理等常規(guī)治療，同時根據(jù)用藥方案，對2組患者進(jìn)行如下施治。 對照組（硝苯地平緩釋片方案）：每次劑量10mg，每日口服2次，此后根據(jù)患者的血壓值將每日劑量調(diào)整至40mg，待血壓值降至正常水平時再改成20mg/d維持，療程共4周。 觀察組（纈沙坦＋氨氯地平方案）：纈沙坦、氨氯地平每次劑量各為80mg和5mg，每日清晨口服1次，療程與對照組相同。 研究結(jié)果： 治療后，觀察組的心絞痛療效是94.1%，要顯著性高于對照組的73.5%，有統(tǒng)計學(xué)意義（P＜0.05）。治療前，2組的收縮壓與舒張壓對比相仿（P＞0.05），經(jīng)治療后均出現(xiàn)改善，且觀察組相比對照組改善更顯著（P＜0.05）。2組用藥期間均有不適出現(xiàn)，其中觀察組發(fā)生率是2.9%，，要相比對照組的17.6%更低（P＜0.05）。 結(jié)論： 1.纈沙坦、氨氯地平，每次劑量各為80mg和5mg，每日清晨口服1次，較硝苯地平緩釋片，每次劑量10mg，每日口服2次，更早改善心絞痛癥狀。 2.纈沙坦、氨氯地平，每次劑量各為80mg和5mg降壓效果更優(yōu)于硝苯地平緩釋片，每次劑量10mg。 3.纈沙坦、氨氯地平，每次劑量各為80mg和5mg患者耐受性良好，對心率及肝功、生化等指標(biāo)影響較小，適于臨床推廣。
[Abstract]:Objectives of the study: To evaluate the clinical efficacy and feasibility of valsartan combined with amlodipine in patients with coronary heart disease and hypertension. Research methods: From May 2013 to May 2014, the patients with coronary heart disease (CHD) complicated with hypertension were divided into two groups (34 patients in each group). The control group was treated with nifedipine sustained release tablets, the observation group was treated with valsartan combined with amlodipine, and the treatment outcome of the two groups was studied. After diagnosis, the patients were given routine treatment such as blood pressure measurement, fluid resuscitation and symptomatic treatment. According to the medication scheme, the two groups were treated as follows. Control group (nifedipine sustained-release tablet regimen: 10mg per dose, twice a day, then adjusted to 40mg daily according to the patient's blood pressure. When blood pressure dropped to normal level, it was maintained at 20 mg / d for 4 weeks. The observation group (valsartan + amlodipine regimen: valsartan, amlodipine 80 mg and 5 mg each time, oral once a day, the course of treatment was the same as the control group. Results of the study: After treatment, the effect of angina pectoris in the observation group was 94.1%, which was significantly higher than that in the control group (73.5%, P < 0.05). Systolic blood pressure and diastolic blood pressure in both groups were similar to those in the control group (P > 0.05), and were improved after treatment, and there was discomfort in the observation group compared with the control group (P < 0.05). The incidence of the observation group was 2.9, which was lower than that of the control group (17.6%, P < 0.05). Conclusion: 1. Valsartan, amlodipine, 80 mg and 5 mg each time, orally once a day, than nifedipine sustained release tablets, 10 mg per dose, 2 times a day. Improve angina symptoms earlier. 2. The antihypertensive effect of valsartan and amlodipine was better than that of nifedipine sustained-release tablets at the dose of 80 mg and 5 mg, respectively, with a dose of 10 mg / time. 3. Valsartan, amlodipine, each dose of 80mg and 5mg patients had good tolerance, had little effect on heart rate, liver function, biochemistry and so on, and was suitable for clinical popularization.
【學(xué)位授予單位】：吉林大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2015
【分類號】：R544.1;R541.4

【參考文獻(xiàn)】

相關(guān)期刊論文 前2條

1 陳國偉;;2005年美國化學(xué)委員會/心臟協(xié)會心力衰竭治療指南淺析及血管緊張素Ⅱ受體阻滯劑在心力衰竭治療中的地位[J];中國全科醫(yī)學(xué);2006年22期

2 王巖通;;用氨氯地平聯(lián)合卡托普利治療原發(fā)性高血壓的療效觀察[J];求醫(yī)問藥(下半月);2013年03期

本文編號：1466062